HCW Biologics (NASDAQ:HCWB) Shares Down 8.9%

HCW Biologics Inc. (NASDAQ:HCWB) fell 8.9% on Monday . The stock traded as low as $1.00 and last traded at $1.02. 13,594 shares traded hands during mid-day trading, a decline of 13% from the average session volume of 15,579 shares. The stock had previously closed at $1.12.

HCW Biologics Stock Performance

The company has a market capitalization of $38.58 million, a price-to-earnings ratio of -1.34 and a beta of 0.93. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.46 and a current ratio of 0.46. The firm has a 50-day simple moving average of $1.26 and a two-hundred day simple moving average of $1.29.

HCW Biologics (NASDAQ:HCWB) last released its earnings results on Wednesday, May 15th. The company reported ($0.20) earnings per share for the quarter. HCW Biologics had a negative net margin of 697.53% and a negative return on equity of 146.76%. The firm had revenue of $1.13 million during the quarter.

Hedge Funds Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Avantax Planning Partners Inc. acquired a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 179,541 shares of the company’s stock, valued at approximately $220,000. Avantax Planning Partners Inc. owned approximately 0.50% of HCW Biologics as of its most recent filing with the Securities & Exchange Commission. 2.96% of the stock is currently owned by hedge funds and other institutional investors.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.